<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Potassium phosphate and sodium phosphate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Potassium phosphate and sodium phosphate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Potassium phosphate and sodium phosphate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9800" href="/d/html/9800.html" rel="external">see "Potassium phosphate and sodium phosphate: Drug information"</a> and <a class="drug drug_patient" data-topicid="12102" href="/d/html/12102.html" rel="external">see "Potassium phosphate and sodium phosphate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F212118"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Av-Phos 250 Neutral;</li>
<li>K-Phos Neutral;</li>
<li>K-Phos No. 2;</li>
<li>Phos-NaK;</li>
<li>Phospha 250 Neutral;</li>
<li>Phospho-Trin 250 Neutral;</li>
<li>Virt-Phos 250 Neutral [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1032536"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Electrolyte Supplement, Oral</span>;</li>
<li>
<span class="list-set-name">Phosphate Salt</span>;</li>
<li>
<span class="list-set-name">Potassium Salt</span>;</li>
<li>
<span class="list-set-name">Sodium Salt</span></li></ul></div>
<div class="block don drugH1Div" id="F53462555"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consider the contribution of sodium and potassium when determining the appropriate phosphate replacement. <b>Note:</b> 1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adequate intake:</b> Recommended intake from dietary sources (eg, breast milk, formula).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Oral: 100 mg <b>elemental </b>phosphorus/day (3.2 mmol <b>elemental </b>phosphorus/day); requirements may vary based on prematurity, postnatal age, and other clinical factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-IOM.1','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-IOM.1','lexi-content-ref-NIH.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3e6ccf5-3766-4dbc-bed0-d5ae6f5e8d7d">Metabolic bone disease or rickets, prevention or treatment of hypophosphatemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic bone disease or rickets, prevention or treatment of hypophosphatemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Preterm Neonates: Oral: Initial: 10 to 20 mg <b>elemental</b> phosphorus/kg/day (0.32 to 0.64 mmol <b>elemental</b> phosphorous/kg/day) in divided doses; may increase as needed to 40 to 50 mg <b>elemental</b> phosphorus/kg/day (1.28 to 1.6 mmol <b>elemental</b> phosphorous/kg/day) in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629620'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F212129"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consider the contribution of sodium and potassium cations when determining appropriate phosphate replacement. Dosing is presented as mg/day and mmol/day; use extra caution. <b>Note:</b> 1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate. Dosage expressed in terms of <b>phosphate/phosphorus</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de032cb1-ec1e-4269-8e0c-b7218680e8a4">Dietary supplementation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplementation:</b> K-Phos Neutral, Phospha 250 Neutral, Phos NaK, Phospho Trin 250 Neutral:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;4 years and Adolescents: Oral: 250 mg <b>elemental</b> phosphorus (1 tablet) 4 times daily (with meals and at bedtime).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad53c361-db38-45d8-b702-fe9ce629c29e">Hypophosphatemia, chronic; prevention or maintenance treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypophosphatemia, chronic; prevention or maintenance treatment: Note:</b> Dose should be individualized and may vary based on underlying etiology.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 2 to 3 <b>mmol</b>
<b>elemental phosphorus</b>/kg/day in divided doses, usually at least 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Greenbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Greenbaum.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c4a1ad65-aed4-44dd-9ba1-3513b597b82f">Internal contamination with radioactive phosphorus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Internal contamination with radioactive phosphorus (P-32): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;4 years and Adolescents: Oral: 250 mg 4 times daily; adolescent dosing not defined in expert recommendations; in adults, doses of 250 to 500 mg 4 times daily suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-REACT.1','lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-REACT.1','lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154220"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; phosphorus accumulates in renal impairment. Contraindicated in patients with severe impairment (&lt;30% of normal function).</p></div>
<div class="block dohp drugH1Div" id="F51154221"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution.</p></div>
<div class="block doa drugH1Div" id="F212121"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9800" href="/d/html/9800.html" rel="external">see "Potassium phosphate and sodium phosphate: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage expressed in terms of <b>elemental phosphorus</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c4a1ad65-aed4-44dd-9ba1-3513b597b82f">Internal contamination with radioactive phosphorus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Internal contamination with radioactive phosphorus (P-32) (off-label use): Oral: </b>250 to 500 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-REACT.1','lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-REACT.1','lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="78736677-b84c-4879-b704-1d4ff298e650">Phosphate supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Phosphate supplement:</b> Oral: 250 to 500 mg 4 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="28c851d2-3cfb-4563-b09f-ed9e68674266">Urinary acidification</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary acidification (K-Phos No. 2):</b> Oral: 250 mg 4 times daily; may be increased to 250 mg every 2 hours when the urine is difficult to acidify (maximum: 2,000 mg/day).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991721"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in the manufacturer’s labeling. Use with caution. Contraindicated in patients with severe impairment (&lt;30% of normal function). </p></div>
<div class="block doha drugH1Div" id="F50989046"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution.</p></div>
<div class="block adr drugH1Div" id="F212101"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, chest pain, edema, lower extremity edema, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Confusion, dizziness, fatigue, headache, heaviness of the legs, numbness, paresthesia, seizure, tingling sensation, tetany (with large doses of phosphate)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Alkalosis, hyperkalemia, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, flatulence, nausea, oral paresthesia, sore throat, stomach pain, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Decreased urine output</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local pain (hands and feet)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia, limb pain, muscle cramps, muscle weakness of the extremities, ostealgia, paralysis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute renal failure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Increased thirst</p></div>
<div class="block coi drugH1Div" id="F212113"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hyperphosphatemia; infected urinary phosphate stones; severe renal  impairment (&lt;30% of normal)</p></div>
<div class="block war drugH1Div" id="F212098"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperphosphatemia: Hyperphosphatemia managed with hemodialysis has been reported following excessive use of sodium phosphate enemas (Becknell 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Laxative effect: A mild laxative effect may occur within the first few days of therapy; if the laxative effect persists, reduce the dose or discontinue use until diarrhea improves.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with severe adrenal insufficiency (eg, Addison disease)</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Use with caution in patients with cardiac disease, including heart failure (especially patients receiving digoxin) and hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dehydration: Use with caution in patients with acute dehydration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edema: Use with caution in patients with peripheral or pulmonary edema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with cirrhosis or severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypernatremia: Use with caution in patients with hypernatremia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myotonia congenita: Use with caution in patients with myotonia congenita.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Use with caution in patients with acute pancreatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parathyroid disease: Use with caution in patients with hypoparathyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal calculi: Patients with renal calculi may pass preformed stones when phosphate therapy is initiated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment or chronic renal disease; use is contraindicated in patient with severe renal impairment (&lt;30% of normal).</p>
<p style="text-indent:-2em;margin-left:4em;">• Rickets: Use with caution in patients with rickets; may increase the risk of extraskeletal calcification.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tissue breakdown: Use with caution in patients with extensive tissue breakdown (eg, severe burns).</p></div>
<div class="block foc drugH1Div" id="F212108"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for solution, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Phos-NaK: Dibasic potassium phosphate, monobasic potassium phosphate, dibasic sodium phosphate, and monobasic sodium phosphate per packet (100s) [sugar free; equivalent to elemental phosphorus 250 mg (8 mmol), sodium 160 mg (6.9 mEq), and potassium 280 mg (7.1 mEq) per packet; fruit flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Dibasic potassium phosphate, monobasic potassium phosphate, dibasic sodium phosphate, and monobasic sodium phosphate per packet</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Av-Phos 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p>
<p style="text-indent:-2em;margin-left:4em;">K-Phos Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p>
<p style="text-indent:-2em;margin-left:4em;">K-Phos No. 2: Potassium acid phosphate 305 mg and sodium acid phosphate 700 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 134 mg (5.8 mEq), and potassium 88 mg (2.3 mEq)]</p>
<p style="text-indent:-2em;margin-left:4em;">Phospha 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p>
<p style="text-indent:-2em;margin-left:4em;">Phospho-Trin 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p>
<p style="text-indent:-2em;margin-left:4em;">Virt-Phos 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)] [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p></div>
<div class="block geq drugH1Div" id="F212095"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F212114"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (K-Phos No 2 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">305-700 mg (per each): $1.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (K-Phos-Neutral Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">155-852-130 mg (per each): $0.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Phospha 250 Neutral Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">155-852-130 mg (per each): $0.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Phospho-Trin 250 Neutral Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">155-852-130 mg (per each): $0.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613636"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Administer with a full glass of water.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral powder (Phos-NaK): Each packet must be diluted in 75 mL of water or juice prior to administration; stir well and use promptly. Proper dilution may help prevent GI injury associated with concentrated oral potassium preparations.</p></div>
<div class="block adm drugH1Div" id="F212110"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with a full glass of water at mealtime and at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oral powder: Must be diluted  in water or juice prior to administration.</p></div>
<div class="block sts drugH1Div" id="F20164069"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral powder: Store at room temperature; protect from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture. Contact of Virt-Phos with moisture may produce surface discoloration or erosion.</p></div>
<div class="block usep drugH1Div" id="F53568459"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment and prevention of hypophosphatemia (Av-Phos 250 Neutral, K-Phos Neutral, Phospha 250 Neutral, Phos NaK, Virt-Phos 250 Neutral: Dietary supplement approved for use in ages &gt;4 years and adults); urinary acidification (K-Phos No. 2: FDA approved in adults); has also been used for internal contamination with radioactive phosphorus (P-32).</p></div>
<div class="block mst drugH1Div" id="F212139"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">K-Phos Neutral may be confused with Neutra-Phos-K [DSC]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299926"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F212103"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Urinary Acidifying Agents may decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Urinary Acidifying Agents may decrease the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AMILoride: Potassium Salts may enhance the hyperkalemic effect of AMILoride.  Management: Amiloride and potassium supplements should not be used except in severe or refractory cases of hypokalemia. If coadministered, monitor serum potassium closely as rapid increases in potassium are possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Urinary Acidifying Agents may decrease the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Potassium Phosphate. Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Burosumab: Phosphate Supplements may enhance the adverse/toxic effect of Burosumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproPAMIDE: Urinary Acidifying Agents may increase the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Potassium supplements may be needed to treat/prevent hypokalemia in select patients with heart failure receiving eplerenone and high dose loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium Salts may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral iron preparation as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Urinary Acidifying Agents may decrease the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an iron-containing oral multivitamin as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: Potassium Phosphate may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Potassium Salts may enhance the hyperkalemic effect of Spironolactone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration. Administering oral phosphate supplements at least 2 hours before sucralfate may reduce the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamterene: Potassium Salts may enhance the hyperkalemic effect of Triamterene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Uva Ursi: Urinary Acidifying Agents may diminish the therapeutic effect of Uva Ursi.  Management: Consider avoiding use of uva ursi with agents that acidify the urine, as this may impair uva ursi efficacy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F212115"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">In addition to phosphate, products contain potassium and sodium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary reference intake (elemental phosphorus) (IOM 1997):</b></p>
<p style="text-indent:-2em;margin-left:4em;">1 to 6 months: Adequate intake: 100 mg/day (3.2 mmol/day).</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months: Adequate intake: 275 mg/day (8.9 mmol/day).</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: Recommended dietary allowance (RDA): 460 mg/day (14.8 mmol/day).</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: RDA: 500 mg/day (16.1 mmol/day).</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 18 years: RDA: 1,250 mg/day (40.3 mmol/day).</p>
<p style="text-indent:-2em;margin-left:4em;">≥18 years: RDA: 700 mg/day (22.6 mmol/day).</p></div>
<div class="block pri drugH1Div" id="F14287312"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use with caution in patients with preeclampsia.</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to individual monographs for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53568435"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum potassium, sodium, calcium, phosphorus, renal function.</p></div>
<div class="block rerp drugH1Div" id="F53568321"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Phosphorous, serum: Note:</b> There is a diurnal variation with the nadir at 1100 hours, plateau at 1600 hours, and peak in the early evening (Gaasbeek 2005); 1 mmol/L phosphate = 3.1 mg/dL phosphorus.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates 0 to 5 days: 4.8 to 8.2 mg/dL (Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to &lt;4 years: 3.8 to 6.5 mg/dL (Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;6 years: 3.7 to 6 mg/dL (Adeli 2015; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: 3.7 to 5.7 mg/dL (Adeli 2015; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents &lt;16 years: 2.9 to 5.9 mg/dL (Adeli 2015; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents 16 to 18 years: 2.7 to 4.7 mg/dL (Adeli 2015; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Potassium, serum:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Neonates &lt;7 days: 3.2 to 5.5 mmol/L (Greeley 1993; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates ≥7 to 30 days: 3.4 to 6 mmol/L (Greeley 1993; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;6 months: 3.5 to 5.6 mmol/L (Greeley 1993; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months: 3.5 to 6.1 mmol/L (Greeley 1993; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;6 years: 3.3 to 4.6 mmol/L (Adeli 2015; Greeley 1993; Kliegman 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: 3.3 to 4.9 mmol/L (Adeli 2015; Greeley 1993; Kliegman 2020).</p></div>
<div class="block pha drugH1Div" id="F45626463"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block phk drugH1Div" id="F212112"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;">Onset of action: Catharsis: Oral: 3 to 6 hours</p>
<p style="text-indent:0em;">Absorption: Oral: 1% to 20% </p>
<p style="text-indent:0em;">Excretion: Oral forms excreted in feces </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58885283"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Phospha Neutral</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23629620">
<a name="23629620"></a>Abrams SA; Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. <i>Pediatrics</i>. 2013;131(5):e1676-e1683. doi:10.1542/peds.2013-0420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-phosphate-and-sodium-phosphate-pediatric-drug-information/abstract-text/23629620/pubmed" id="23629620" target="_blank">23629620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26044506">
<a name="26044506"></a>Adeli K, Higgins V, Nieuwesteeg M, et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. <i>Clin Chem</i>. 2015;61(8):1049-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-phosphate-and-sodium-phosphate-pediatric-drug-information/abstract-text/26044506/pubmed" id="26044506" target="_blank">26044506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Av-Phos.1">
<a name="Av-Phos.1"></a>Av-Phos 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Pulaski, TN: AvKare, Inc; May 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25373567">
<a name="25373567"></a>Becknell B, Smoyer WE, O'Brien NF. Hemodialysis for near-fatal sodium phosphate toxicity in a child receiving sodium phosphate enemas. <i>Pediatr Emerg Care</i>. 2014;30(11):814-817. doi:10.1097/PEC.0000000000000267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-phosphate-and-sodium-phosphate-pediatric-drug-information/abstract-text/25373567/pubmed" id="25373567" target="_blank">25373567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16194637">
<a name="16194637"></a>Gaasbeek A and Meinders AE, “Hypophosphatemia: An Update on Its Etiology and Treatment,”<i> Am J Med</i>, 2005, 118(10):1094-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-phosphate-and-sodium-phosphate-pediatric-drug-information/abstract-text/16194637/pubmed" id="16194637" target="_blank">16194637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greeley.1">
<a name="Greeley.1"></a>Greeley C, Snell J, Colaco A, et al. Pediatric reference ranges for electrolytes and creatinine. <i>Clin Chem</i>. 1993;39(6):1172.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greenbaum.1">
<a name="Greenbaum.1"></a>Greenbaum LA. Phosphorus. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap. 68.6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine), Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride, National Academy of Sciences, Washington, DC, 1997.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-K-Phos.1">
<a name="K-Phos.1"></a>K-Phos Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; June 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-K-Phos.3">
<a name="K-Phos.3"></a>K-Phos Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-K-Phos.2">
<a name="K-Phos.2"></a>K-Phos No. 2 (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-K-Phos.4">
<a name="K-Phos.4"></a>K-Phos No. 2 (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2">
<a name="Kliegman.2"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). Phosphorus fact sheet for health professionals. <a href="https://ods.od.nih.gov/factsheets/Phosphorus-HealthProfessional/" target="_blank">https://ods.od.nih.gov/factsheets/Phosphorus-HealthProfessional/</a>. Updated March 26, 2021. Accessed March 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phos-NaK.1">
<a name="Phos-NaK.1"></a>Phos-NaK (potassium phosphate/sodium phosphate) [prescribing information]. Morristown, NJ: Cypress Pharmaceutical; received November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phospha.1">
<a name="Phospha.1"></a>Phospha 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Columbus, OH: American Health Packaging; April 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phospha.2">
<a name="Phospha.2"></a>Phospha 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Saddle Brook, NJ: Rising Pharmaceuticals Inc; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phospho-Trin.1">
<a name="Phospho-Trin.1"></a>Phospho-Trin 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Skokie, IL: Patrin Pharma; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-REACT.1">
<a name="REACT.1"></a>Radiation Emergency Assistance Center/Training Site (REACT/TS). The medical aspects of radiation incidents. 4th ed. <a href="https://orise.orau.gov/resources/reacts/documents/medical-aspects-of-radiation-incidents.pdf" target="_blank">https://orise.orau.gov/resources/reacts/documents/medical-aspects-of-radiation-incidents.pdf</a>. Updated July 2017. Accessed February 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022">
<a name="HHS.2022"></a>US Department of Health and Human Services (HHS) Radiation Emergency Medical Management (REMM). Managing internal radiation contamination. <a href="https://remm.hhs.gov/int_contamination.htm#blockingagents_2" target="_blank">https://remm.hhs.gov/int_contamination.htm#blockingagents_2</a>. Updated February 17, 2022. Accessed February 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Virt-Phos.1">
<a name="Virt-Phos.1"></a>Virt-Phos 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Virtus Pharmaceuticals; May 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Virt-Phos.2">
<a name="Virt-Phos.2"></a>Virt-Phos 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Virtus Pharmaceuticals; May 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12986 Version 145.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
